Michelle Jones-London, Ph.D.

Job Title
Associate Director, Office of Programs to Enhance the Neuroscience Workforce
Photo of Michelle D. Jones-London, PhD
Office of Programs to Enhance the Neuroscience Workforce
Areas of Interest

Workforce Diversity

Contact Email
Contact Number

Michelle Jones-London serves as the Associate Director of the Office of Programs to Enhance the Neuroscience Workforce (OPEN) in the NINDS Office of the Director. She leads the NINDS’s scientifically driven efforts in three complementary but unique domains. The first is to improve neuroscience research and the Nation’s neurological health through neuroscience research training and career development programs throughout the country and in our intramural research program; the second is to promote a welcoming environment for all members of the internal NINDS workforce to advance the Institute’s mission; and third is to use evidence-based approaches to catalyze cultures of inclusive excellence in the neuroscience research community.

Dr. Jones-London joined NINDS as a Program Director in July 2006. Dr. Jones-London earned her PhD in Neuroscience from Pennsylvania State University College of Medicine. She then received postdoctoral training as a research fellow at University of Pennsylvania. Dr. Jones-London came to the NIH in July 2004 as an Emerging Leader Fellow. She performed duties across the Department of Health and Human Services including the Center for Scientific Review, FDA Office of Women's Health Science Program, and the Immediate Office of the Secretary, Intergovernmental/Tribal Affairs Office. Her trans-NIH efforts have included oversight for the NIH Blueprint & BRAIN Initiative® ENDURE and DSPAN (F99/K00) programs, the BRAIN Initiative® Diversity K99/R00, former Project Scientist for the NIH National Research Mentoring Network (NRMN) and part of the leadership team for NIH Faculty Institutional Recruitment for Sustainable Transformation (FIRST). Her research interests have focused on understanding monoaminergic neurotransmitter regulation and mechanisms of behavioral psychopharmacology in animal models of disorders such as ADHD, Tourette Syndrome, and depression.